Stryker Corporation (NYSE:SYK)‘s stock had its “hold” rating reissued by investment analysts at Needham & Company LLC in a research report issued on Friday.

Other equities research analysts also recently issued reports about the stock. BMO Capital Markets reissued a “hold” rating and set a $140.00 target price on shares of Stryker Corporation in a research report on Tuesday, July 11th. Wells Fargo & Company boosted their target price on shares of Stryker Corporation from $160.00 to $166.00 in a research report on Friday, October 27th. Barclays PLC boosted their target price on shares of Stryker Corporation from $137.00 to $148.00 and gave the stock an “underweight” rating in a research report on Friday, October 27th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Stryker Corporation in a research report on Wednesday, August 23rd. Finally, Morgan Stanley reissued an “overweight” rating and set a $160.00 target price (up from $155.00) on shares of Stryker Corporation in a research report on Monday, July 10th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the company’s stock. Stryker Corporation currently has a consensus rating of “Hold” and an average target price of $151.52.

Stryker Corporation (NYSE:SYK) traded up $1.16 on Friday, reaching $156.18. 1,153,984 shares of the company’s stock traded hands, compared to its average volume of 1,302,000. Stryker Corporation has a 12-month low of $106.48 and a 12-month high of $160.62. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $58,448.49, a P/E ratio of 24.75, a P/E/G ratio of 2.46 and a beta of 0.79.

Stryker Corporation (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.02. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. The firm had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the previous year, the firm posted $1.39 earnings per share. The business’s revenue was up 6.1% compared to the same quarter last year. analysts forecast that Stryker Corporation will post 6.47 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/stryker-corporation-syk-rating-reiterated-by-needham-company-llc/1680843.html.

In other Stryker Corporation news, insider Graham A. Mclean sold 1,124 shares of the business’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total value of $164,396.24. Following the transaction, the insider now directly owns 8,983 shares in the company, valued at $1,313,853.58. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.40% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the stock. Global X MANAGEMENT CO LLC lifted its stake in shares of Stryker Corporation by 15.1% during the 3rd quarter. Global X MANAGEMENT CO LLC now owns 6,573 shares of the medical technology company’s stock valued at $933,000 after buying an additional 862 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its stake in shares of Stryker Corporation by 0.9% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 47,796 shares of the medical technology company’s stock valued at $6,788,000 after buying an additional 446 shares in the last quarter. Brown Advisory Securities LLC lifted its stake in shares of Stryker Corporation by 8.1% during the 3rd quarter. Brown Advisory Securities LLC now owns 12,756 shares of the medical technology company’s stock valued at $1,811,000 after buying an additional 959 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Stryker Corporation by 756.6% during the 3rd quarter. Bessemer Group Inc. now owns 39,566 shares of the medical technology company’s stock valued at $5,620,000 after buying an additional 34,947 shares in the last quarter. Finally, Advantus Capital Management Inc lifted its stake in shares of Stryker Corporation by 4.2% during the 3rd quarter. Advantus Capital Management Inc now owns 32,693 shares of the medical technology company’s stock valued at $4,643,000 after buying an additional 1,316 shares in the last quarter. Institutional investors own 74.00% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.